Ryosuke Oki
Overview
Explore the profile of Ryosuke Oki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
160
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Urasaki T, Ono M, Yamashita K, Tanizawa T, Togashi Y, Ohmoto A, et al.
Oncol Lett
. 2025 Jan;
29(3):108.
PMID: 39776650
sarcoma is rare and its clinical features remain unclear. Given the similarity in presentation, it is possible that previously reported cases of Ewing-like adamantinoma may have been sarcoma. The present...
2.
Sato K, Takemura K, Oki R, Urasaki T, Yoneoka Y, Fujiwara R, et al.
Urol Oncol
. 2025 Jan;
43(4):269.e1-269.e6.
PMID: 39757037
Objectives: Higher body mass index (BMI) is reportedly associated with improved prognosis of patients with various cancers. However, it is unclear whether this phenomenon, also known as the obesity paradox,...
3.
Yasuda Y, Numao N, Urasaki T, Oki R, Oguchi T, Fujiwara R, et al.
Int J Clin Oncol
. 2024 Sep;
29(12):1925-1930.
PMID: 39264379
Background: The phase 3 CheckMate 274 trial demonstrated superiority of adjuvant nivolumab over placebo after radical surgery in patients with high-risk urothelial carcinoma (UC). However, real-world data on the efficacy...
4.
Kaji R, Izumi Y, Oki R
Curr Opin Neurol
. 2024 Jul;
37(5):593-602.
PMID: 39083229
Purpose Of Review: Recent development in understanding the pathophysiology of amyotrophic lateral sclerosis (ALS) has led to increasing number of promising test drugs in the pipeline along with the existing...
5.
Fukuda N, Toda K, Suto H, Oki R, Wang X, Urasaki T, et al.
Endocr J
. 2024 Jan;
71(4):363-371.
PMID: 38296547
Proteinuria has been described as a major on-target adverse event of lenvatinib, although its long-term impact on renal function and clinical outcomes remains unclear. We conducted a retrospective observational study...
6.
Une M, Fujiwara R, Ueki A, Oki R, Urasaki T, Inamura K, et al.
IJU Case Rep
. 2023 Sep;
6(5):286-289.
PMID: 37667764
Introduction: Li-Fraumeni syndrome, an autosomal dominant cancer predisposition syndrome caused by a pathogenic variant of , a tumor suppressor gene, leads to a high risk from early childhood of developing...
7.
Fukuda N, Oki R, Suto H, Wang X, Urasaki T, Sato Y, et al.
Oncology
. 2023 Jul;
101(8):502-511.
PMID: 37429272
Introduction: Although systemic therapy, including multi-kinase inhibitors and cytotoxic chemotherapy, is an option for recurrent or metastatic adenoid cystic carcinoma of the head and neck (HNACC), it is not proven...
8.
Yasuda Y, Fujiwara R, Oguchi T, Komai Y, Numao N, Yamamoto S, et al.
Cancer Diagn Progn
. 2023 May;
3(3):327-333.
PMID: 37168959
Background/aim: Immune-related adverse events (irAEs) develop in a subset of patients with metastatic renal cell carcinoma (mRCC) treated with immune-checkpoint-inhibitors (ICIs). Evidence regarding the prognostic impact of irAEs remains limited...
9.
Ohmoto A, Nakano K, Fukuda N, Wang X, Urasaki T, Hayashi N, et al.
PLoS One
. 2023 Mar;
18(3):e0280508.
PMID: 36857355
Trabectedin is a therapeutic option for patients with advanced sarcoma. While a randomized trial demonstrated its prolonged progression-free survival (PFS), the reported PFS was <6 months. Some patients can achieve...
10.
Haji S, Fujita K, Oki R, Osaki Y, Miyamoto R, Morino H, et al.
JMIR Res Protoc
. 2023 Jan;
12:e42032.
PMID: 36716091
Background: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder, with its currently approved drugs, including riluzole and edaravone, showing limited therapeutic effects. Therefore, safe and effective drugs are urgently...